Midtreatment 18F-fluorodeoxyglucose positron-emission tomography in aggressive non-Hodgkin lymphoma. - Wikidata - wikimedia - TriplyDB

Midtreatment 18F-fluorodeoxyglucose positron-emission tomography in aggressive non-Hodgkin lymphoma.

Midtreatment 18F-fluorodeoxyglucose positron-emission tomography in aggressive non-Hodgkin lymphoma.

http://www.wikidata.org/entity/Q51646044

about

PET Scans for Staging and Restaging in Diffuse Large B-Cell and Follicular Lymphomas The use of FDG-PET in diffuse large B cell lymphoma (DLBCL): predicting outcome following first line therapy The role of FDG-PET imaging as a prognostic marker of outcome in primary mediastinal B-cell lymphoma.Prognostic significance of metabolic tumor burden by positron emission tomography/computed tomography in patients with relapsed/refractory diffuse large B-cell lymphoma.FDG-PET/CT based response-adapted treatment.Response-adapted therapy for aggressive non-Hodgkin's lymphomas based on early [18F] FDG-PET scanning: ECOG-ACRIN Cancer Research Group study (E3404)Combination of baseline metabolic tumour volume and early response on PET/CT improves progression-free survival prediction in DLBCL.Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group.18F-fluorodeoxyglucose positron emission tomography in the staging and prognosis of T cell lymphoma.Utility of baseline, interim and end-of-treatment 18F-FDG PET/CT in extranodal natural killer/T-cell lymphoma patients treated with L-asparaginase/pegaspargase.Positron emission tomography findings in clinical mimics of lymphoma.[¹⁸F]fluoro-2-deoxy-d-glucose positron emission tomography/computed tomography imaging in oncology: initial staging and evaluation of cancer therapy When should FDG-PET be used in the modern management of lymphoma?Current role of FDG PET/CT in lymphoma.Intensification treatment based on early FDG-PET in patients with high-risk diffuse large B-cell lymphoma: a phase II GELTAMO trial.FDG PET for therapy monitoring in Hodgkin and non-Hodgkin lymphomas.Malignant lymphoma with diffuse cardiac involvement detected by multiple imaging examinations: a case report.FDG-PET in Follicular Lymphoma Management The predictive value of interim and final [18F] fluorodeoxyglucose positron emission tomography after rituximab-chemotherapy in the treatment of non-Hodgkin's lymphoma: a meta-analysis.Predictive value of interim PET/CT visual interpretation in the prognosis of patients with aggressive non-Hodgkin's lymphoma.Different predictive values of interim 18F-FDG PET/CT in germinal center like and non-germinal center like diffuse large B-cell lymphoma.Evaluating early interim fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography with the SUVmax-liver-based interpretation for predicting the outcome in diffuse large B-cell lymphoma.(18)F-fluorodeoxyglucose-positron emission tomography/computed tomography after one cycle of chemotherapy in patients with diffuse large B-cell lymphoma: results of a Nordic/US intergroup study.Use of interim [18F]fluorodeoxyglucose-positron emission tomography is not justified in diffuse large B-cell lymphoma during first-line immunochemotherapy.Guidelines for the management of diffuse large B-cell lymphoma.

P2860

Q26752284-9370EED4-9C69-4C0C-826D-98203479387D Q26863624-F5ED1E12-BBFD-4AA7-9CB1-E63235A5036B Q35032285-1E7FA26D-85D9-4091-A586-08C892ACE637 Q35439403-94CA16CC-2467-4625-8443-5752D44B51AE Q36286595-47DB892A-DF5F-4BE0-870B-5C1E829A9D59 Q36417808-9C859952-43B4-456B-ABE8-39C9B7A3D9D2 Q36897012-697C2B91-D905-47FC-A7C7-709E3BB87FB6 Q37240835-40B23169-7CFE-4F8B-A034-4EF47A4C8811 Q37561054-7F592E0D-A6A7-4FB9-B514-1055178D0A56 Q37602246-06FD8080-3F81-47D4-80DE-148D6ADACE25 Q37896130-6688ACF1-847F-41A1-B4A9-303CFB8415F7 Q38077874-1896B4DF-1428-4C2E-B8BB-2BD1BB828DBA Q38153086-B9DEB00C-B2B2-4B96-AAD9-99A3822B2B95 Q38187365-405E5603-581B-4180-86E8-FF8EAED36BCC Q38234470-B5F45F08-39F9-4DDA-8466-A5A090A5FF8E Q38836081-B88A5DB4-C2B6-43B2-9269-36B777A36E8E Q41819401-9B815CCF-6AB2-40C6-8FF7-A334AFAE5639 Q41840128-983B8B95-5469-44E8-8A77-D168844862D4 Q42033589-D84DD594-A128-4DB0-9126-5070BAB73646 Q47252205-944D0F65-BC41-4980-8329-EAA14F1DE10D Q48355928-54E38431-26E6-4418-904E-0410406B5BAE Q52941794-E19BB95E-E517-43A2-9FA6-B544BC0FEAA1 Q53082718-11B1EA71-15BA-49F8-82FC-CB60BB24649C Q53207684-1C4C5146-71BE-4C0B-AF64-2EF5ADAE7EA9 Q54708579-E787E23F-7B53-438C-AF6B-1CDF429D7674

P2860

Midtreatment 18F-fluorodeoxyglucose positron-emission tomography in aggressive non-Hodgkin lymphoma.

http://www.wikidata.org/entity/Q51646044

description

2010 nî lūn-bûn

@nan

2010年の論文

@ja

2010年学术文章

@wuu

2010年学术文章

@zh

2010年学术文章

@zh-cn

2010年学术文章

@zh-hans

2010年学术文章

@zh-my

2010年学术文章

@zh-sg

2010年學術文章

@yue

2010年學術文章

@zh-hant

name

Midtreatment 18F-fluorodeoxygl ...... gressive non-Hodgkin lymphoma.

@en

Midtreatment 18F-fluorodeoxygl ...... gressive non-Hodgkin lymphoma.

@nl

type

label

Midtreatment 18F-fluorodeoxygl ...... gressive non-Hodgkin lymphoma.

@en

Midtreatment 18F-fluorodeoxygl ...... gressive non-Hodgkin lymphoma.

@nl

prefLabel

Midtreatment 18F-fluorodeoxygl ...... gressive non-Hodgkin lymphoma.

@en

Midtreatment 18F-fluorodeoxygl ...... gressive non-Hodgkin lymphoma.

@nl

P1433

Q51646044-BD458EF2-0553-4D2F-A932-314E295528F9

P1476

Q51646044-1D717E04-E59B-4D12-9761-D105FC98D45D

P2093

Q51646044-11126B9E-8738-4C38-8E17-E0FA8B2DDF5D

Q51646044-27FAD61A-121F-489C-98AD-421EBDE7E7B2

Q51646044-2F020BE1-D0EC-4E0E-849B-B7FC3E9A28F0

Q51646044-33A38073-3211-47D5-A0F0-A1BFB1683411

Q51646044-5C3FC252-12C4-4E51-B681-41401F9B74CA

Q51646044-6E4523CD-C3F8-426E-B349-88217B8E25B7

Q51646044-EFAFCF45-D88B-4501-989A-19DFE2313F94

P2860

Q51646044-02770C57-0FBB-4F51-A570-B16713BCCEB6

Q51646044-092DAAF4-E44B-47A7-8B0B-60554D63160A

Q51646044-0AFC4284-F68D-4055-93F6-CF86E784A8AC

Q51646044-0B6A2B85-5916-457D-8EA5-79195BF0B9C3

Q51646044-186E718B-4E1B-4601-8B0D-85CE4B2AB881

Q51646044-1BB19ABF-A68D-41A7-856C-AE2FAD702A51

Q51646044-2D16DE9E-D978-4B2D-A3E6-C423595094C6

Q51646044-2E4E63B7-B6E1-4AE3-8DEE-B48FFBFEA11C

Q51646044-37782A49-2BB1-46BB-BD53-A03BA0EBC890

Q51646044-48538C39-85DD-407A-B95D-517A762453D1

P304

Q51646044-48F47124-E441-4AB2-AD60-97FE7AD63190

P31

Q51646044-40621BB0-B318-4E2A-858E-4B45AE81A58D

P356

Q51646044-0DF45E41-C084-469B-A565-ECB7D66EB7E8

P407

Q51646044-64E8BC5E-B33F-4EC7-BB2F-61C44BC53D35

P433

Q51646044-461AC968-8AC3-40F1-A40E-1C94028E6000

P478

Q51646044-6FD8E5F7-63A9-4F74-B087-C118C3A49D04

P50

Q51646044-5E3B0724-3BB4-4D92-9BE5-F7FAC3F75BD0

Q51646044-8415C9AA-6D8F-4FDD-AF95-AACC9734BE17

Q51646044-F45D691D-B55F-44D8-B2CB-7D6CDC3EACE1

P577

Q51646044-1372B8FE-4FF5-4471-B385-59D9F3ED2E8D

P5875

Q51646044-E3615F89-E15C-45D6-8F34-56B6657B742A

P698

Q51646044-08E13CE1-7D05-4A53-B5CB-EE42D3C7634A

P356

P1433

P1476

Midtreatment 18F-fluorodeoxygl ...... gressive non-Hodgkin lymphoma.

@en

P2093

Alessandro Broccoli

http://www.w3.org/2001/XMLSchema#string

Cinzia Pellegrini

http://www.w3.org/2001/XMLSchema#string

Federica Quirini

http://www.w3.org/2001/XMLSchema#string

Letizia Gandolfi

http://www.w3.org/2001/XMLSchema#string

Lisa Argnani

http://www.w3.org/2001/XMLSchema#string

Stefano Fanti

http://www.w3.org/2001/XMLSchema#string

Vittorio Stefoni

http://www.w3.org/2001/XMLSchema#string

P2860

The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma.

Stromal gene signatures in large-B-cell lymphomas

Phase II study of risk-adapted therapy of newly diagnosed, aggressive non-Hodgkin lymphoma based on midtreatment FDG-PET scanning.

Interim positron emission tomography scans in diffuse large B-cell lymphoma: an independent expert nuclear medicine evaluation of the Eastern Cooperative Oncology Group E3404 study.

Shortened first-line high-dose chemotherapy for patients with poor-prognosis aggressive lymphoma.

High incidence of false-positive PET scans in patients with aggressive non-Hodgkin's lymphoma treated with rituximab-containing regimens.

Fluorine-18-fluorodeoxyglucose positron emission tomography for interim response assessment of advanced-stage Hodgkin's lymphoma and diffuse large B-cell lymphoma: a systematic review.

PET/CT for therapy response assessment in lymphoma.

Interim fluorodeoxyglucose positron emission tomography for early response assessment in diffuse large B cell lymphoma: where are we now?

CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.

P304

1010-1018

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/CNCR.25579

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

117

http://www.w3.org/2001/XMLSchema#string

P50

Enrico Derenzini

Pier Luigi Zinzani

Michele Baccarani

P577

2010-10-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

47501023

http://www.w3.org/2001/XMLSchema#string

P698

20960498

http://www.w3.org/2001/XMLSchema#string